从分子病理学到当前治疗和临床试验的非分化冠状腺瘤
Weronika Zając1,2, Julia Dróżdż1,2, Weronika Kisielewska1,2
1Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Cancers
|August 12, 2023
概括
分离性软骨瘤 (DDCS) 是一种罕见的,有攻击性的骨癌,预后不佳,转移风险高. 标准治疗包括手术,化学疗法,并遵循晚期骨髓瘤病例的治疗方案.
科学领域:
- 整形瘤学 整形瘤学
- 骨辐射学 骨辐射学
- 手术病理学手术病理学
背景情况:
- 分离性软骨肉瘤 (DDCS) 是一种罕见的恶性瘤,占所有软骨肉瘤的1-2%.
- DDCS的特点是积极的临床过程,高转移潜力和不良预后,五年生存率在7%至24%之间.
- 呈现的平均年龄在50岁以上,常见的部位包括股骨,骨盆,手臂,肩膀,肋骨和骨.
研究的目的:
- 为了提供一个全面的概述非差异化软骨肉瘤.
- 突出与DDCS相关的诊断和治疗挑战.
- 为了强调这种罕见的骨肉瘤的不良预后和治疗策略.
主要方法:
- 综述关于非分化性软骨肉瘤的现有文献.
- 对流行病学数据的分析,包括发病年龄和常见地点.
- 目前治疗方式的总结,包括手术切除和化疗.
主要成果:
- DDCS代表了一小部分,但极具侵略性的冠状腺瘤.
- 转移是常见的并发症,导致低生存率.
- 手术切除是局部疾病的主要治疗方法.
结论:
- 无差异性软骨肉瘤需要专门的管理,因为它具有攻击性.
- 通常用于骨髓瘤的化疗方案适用于DDCS.
- 早期诊断和多学科治疗方法对于改善结果至关重要.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K